Feng, Xiaodong_ Xie, Hong-Guang - Applying pharmacogenomics in therapeutics-CRC Press (2016)

68 Applying Pharmacogenomics in Therapeutics
24. Zhang W, Duan S, Kistner EO, et al. Evaluation of genetic variation contributing to
differences in gene expression between populations. American Journal of Human
Genetics 2008;82:631–40.
25. Zhang W, Dolan ME. Use of cell lines in the investigation of pharmacogenetic loci.
Current Pharmaceutical Design 2009;15:3782–95.
26. Welsh M, Mangravite L, Medina MW, et al. Pharmacogenomic discovery using cellbased
models. Pharmacological Reviews 2009;61:413–29.
27. Huang RS, Duan S, Shukla SJ, et al. Identification of genetic variants contributing to
cisplatin-induced cytotoxicity by use of a genomewide approach. American Journal of
Human Genetics 2007;81:427–37.
28. Huang RS, Duan S, Bleibel WK, et al. A genome-wide approach to identify genetic
variants that contribute to etoposide-induced cytotoxicity. Proceedings of the National
Academy of Sciences of the United States of America 2007;104:9758–63.
29. Huang RS, Duan S, Kistner EO, et al. Genetic variants contributing to daunorubicininduced
cytotoxicity. Cancer Research 2008;68:3161–8.
30. Zhang W, Zheng Y, Hou L. Pharmacogenomic discovery delineating the genetic basis
of drug response. Current Genetic Medicine Reports 2013;1:143–9.
31. Whirl-Carrillo M, McDonagh EM, Hebert JM, et al. Pharmacogenomics knowledge
for personalized medicine. Clinical Pharmacology and Therapeutics 2012;92:414–7.
32. Relling MV, Klein TE. CPIC: Clinical Pharmacogenetics Implementation Consortium
of the Pharmacogenomics Research Network. Clinical Pharmacology and Therapeutics
2011;89:464–7.
33. Giacomini KM, Brett CM, Altman RB, et al. The pharmacogenetics research network:
From SNP discovery to clinical drug response. Clinical Pharmacology and
Therapeutics 2007;81:328–45.
34. Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its
drug and food interactions. Archives of Internal Medicine 2005;165:1095–106.
35. Kamali F, Wynne H. Pharmacogenetics of warfarin. Annual Review of Medicine
2010;61:63–75.
36. Klein TE, Altman RB, Eriksson N, et al. Estimation of the warfarin dose with clinical
and pharmacogenetic data. The New England Journal of Medicine 2009;360:753–64.
37. Gage BF, Eby C, Johnson JA, et al. Use of pharmacogenetic and clinical factors to
predict the therapeutic dose of warfarin. Clinical Pharmacology and Therapeutics
2008;84:326–31.
38. Jonas DE, McLeod HL. Genetic and clinical factors relating to warfarin dosing. Trends
in Pharmacological Sciences 2009;30:375–86.
39. Puehringer H, Loreth RM, Klose G, et al. VKORC1 -1639G>A and CYP2C9*3 are the
major genetic predictors of phenprocoumon dose requirement. European Journal of
Clinical Pharmacology 2010;66:591–8.
40. Higashi MK, Veenstra DL, Kondo LM, et al. Association between CYP2C9 genetic
variants and anticoagulation-related outcomes during warfarin therapy. JAMA
2002;287:1690–8.
41. Aithal GP, Day CP, Kesteven PJ, Daly AK. Association of polymorphisms in the cytochrome
P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications.
The Lancet 1999;353:717–9.
42. Lindh JD, Holm L, Andersson ML, Rane A. Influence of CYP2C9 genotype on warfarin
dose requirements—A systematic review and meta-analysis. European Journal of
Clinical Pharmacology 2009;65:365–75.
43. Sistonen J, Fuselli S, Palo JU, Chauhan N, Padh H, Sajantila A. Pharmacogenetic
variation at CYP2C9, CYP2C19, and CYP2D6 at global and microgeographic scales.
Pharmacogenetics and Genomics 2009;19:170–9.